Chemotherapy cycles in study group (n=182) | Chemotherapy cycles in control group (n=483) | P value | |
Age (year), mean±SD | 54.1±10.5 | 52.9±7.1 | 0.091 |
Body height (m), mean±SD | 58.6±6.9 | 57.9±7.1 | 0.286 |
Body weight (kg), mean±SD | 160.2±4.7 | 160.8±4.5 | 0.094 |
Body mass index (kg/m2), mean±SD | 22.8±2.4 | 22.4±2.8 | 0.064 |
ECOG performance status n (%) | 0.151 | ||
0 | 105 (57.7%) | 275 (65.0%) | |
1 | 54 (29.7%) | 112 (26.5%) | |
2 | 23 (12.6%) | 36 (8.5%) | |
FIGO stage, n (%) | 0.274 | ||
I | 27 (14.8%) | 48 (11.3%) | |
II | 7 (3.8%) | 16 (3.8%) | |
III | 122 (67.0%) | 273 (64.5%) | |
IV | 26 (14.3%) | 86 (20.3%) | |
History of radiotherapy, n (%) | 8 (4.4%) | 16 (3.8%) | 0.439 |
Complications, n (%) | |||
Hypertension | 34 (18.7%) | 97 (22.9%) | 0.244 |
Diabetes | 7 (3.8%) | 35 (8.3%) | 0.049 |
Cardiovascular disease | 0 (0%) | 6 (1.4%) | 0.186 |
Cerebrovascular disease | 0 (0%) | 17 (4.0%) | 0.006 |
DVT | 16 (8.8%) | 36 (8.5%) | 0.910 |
Chemotherapy cycles, mean±SD | 0.417 | ||
≤6 | 141 (77.5%) | 340 (80.4%) | |
>6 | 41 (22.5%) | 83 (19.6%) | |
Chemotherapy regimen, n (%) | 0.074 | ||
PC | 173 (95.1%) | 384 (90.8%) | |
Others | 9 (4.9%) | 39 (9.2%) | |
Bevacizumab, n (%) | 15 (8.2%) | 68 (16.1%) | 0.010 |
Debulking surgery, n (%) | 24 (13.2%) | 55 (13.0%) | 0.951 |
DVT, Deep Venous Thrombosis; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynaecology and Obstetrics; PC, paclitaxel plus carboplatin.